We must continue to engage local investigators and develop their capacity to conduct more basic and clinical research on the African continent.

Influenza, like HIV, is a highly variable menace. A particularly bad flu season has researchers seeking ways to make a better vaccine, and in doing so, there may be lessons from, and for, HIV vaccine research.

Over hundreds of years, researchers have matched contemporary scientific tools to address the infectious disease threats of their times.

Maria Grazia Pau, senior director, compound development team leader for HIV vaccine programs at the Janssen Pharmaceutical Companies of Johnson & Johnson, talks with IAVI Report about the start of the company’s Phase III Mosaico trial.

Drone delivery may help overcome the challenge of getting medicines and vaccines to hard-to-reach populations.

Marianne Mureithi is part of a team of researchers that just received highly competitive funding to study mucosal immune responses to HIV in Kenya.

In a few weeks, the AIDS 2018 meeting will kick off in Amsterdam. It will be the 22nd annual conference, and remains the largest international gathering focused on a single public health issue. This year, one message that will come out loud and clear is that more than 30 years later, AIDS isn’t over. As…

Several areas of progress in using antibodies for HIV prevention were showcased at the recent Keystone Symposia.

Remembering Bonnie Mathieson: A champion of young scientists

Jonathan Quick describes how the right mix of science, funding, leadership, and communication can come together to secure the world against future epidemics.